Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
Conditions: Triple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer Interventions: Drug: INT230-6; Other: neoadjuvant immuno-chemotherapy Sponsors: Swiss Group for Clinical Cancer Research Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research | Switzerland Health